10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
US biotech major Gilead Sciencestoday announced that Johanna Mercier will join the company as chief commercial officer, and will become a member of the company’s senior leadership team. 29 May 2019
Juvenescence, a privately-held investment firm with a focus on increasing healthy human longevity, has announced the creation of a new biotech company to target the epigenetic underpinnings of neurodegeneration. 29 May 2019
Phase III findings on BioMarin Pharmaceutical’s valoctocogene roxaparvovec were announced on Tuesday, leading the US biotech’s share value to fall by 5% by the close. 29 May 2019
The US Food and Drug Administration has approved Revlimid (lenalidomide) in combination with a rituximab product (R²) for the treatment of adult patients with previously treated follicular lymphoma (FL) or marginal zone lymphoma (MZL) following Priority Review designation. 29 May 2019
US pharma major has signed a licensing agreement to acquire the exclusive worldwide rights for CNTX-0290 from privately-held US pain specialist Centrexion Therapeutics Corporation. 28 May 2019
Cambridge, Massachusetts-based genome editing company Intellia Therapeutics has named Laura Sepp-Lorenzino as its new executive vice president and chief scientific officer. 28 May 2019
Dutch biotech firm Synaffix announced that ADC Therapeutics has triggered a third target-specific license under its existing commercial license agreement dated October 2016. 28 May 2019
Italian biopharma Newron Pharmaceuticals looked set to close around 13% down on Tuesday after bad news was announced surrounding evenamide, a potential add-on therapy for the treatment of patients with positive symptoms of schizophrenia. 28 May 2019
The US Food and Drug Administration has approved Jakafi (ruxolitinib) for the treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older 28 May 2019
The US Food and Drug Administration on Friday approved Zolgensma (onasemnogene abeparvovec-xioi), the first gene therapy approved to treat children less than two years of age with spinal muscular atrophy (SMA), the most severe form of SMA and a leading genetic cause of infant mortality. 25 May 2019
Investors stand to play a crucial role in driving healthcare sustainability as well as supporting scientific innovation, write Nathalie Flury and Michael Schröter, founding partners at Swiss asset manager Viopas Partners, and Kate Dion, healthcare value communications consultant at 3D Communications, in an Expert View piece. 24 May 2019
Medical data provider Cegedim has announced a collaboration with French pharma major Sanofi (Euronext: SAN) to use real world evidence to improve healthcare in Europe. 24 May 2019
As industry majors prepare to make a splash at the upcoming annual meeting of the American Society of Clinical Oncology (ASCO), 2003-founded nanomedicine specialist Nanobiotix hopes it can punch above its weight. 24 May 2019
China must take measures to largely improve its clinical data quality to be a competitive player in the global biotech market, said speakers at China’s recent clinical development summit held in Shanghai, reports The Pharma Letter’s local correspondent Wang Fangqing. 24 May 2019
Biotherapeutics revealed that the US Food and Drug Administration has granted Breakthrough Therapy designation for its TIL therapy candidate LN-145 in recurrent, metastatic, or persistent cervical cancer with disease progression on or after chemotherapy. 24 May 2019
The Province of Ontario has become Canada’s first to reimburse Venclexta (venetoclax) monotherapy under its Drugs and Devices Division's (DDD) Exceptional Access Program. 23 May 2019
Akrevia Therapeutics, a privately-held biopharma that was launched in September 2018 by Atlas and F-Prime, has now named its first chief executive. 23 May 2019
US biotech Nektar Therapeutics today announced the formation of Inheris Biopharma, a wholly-owned subsidiary of Nektar and a central nervous system (CNS)-focused company, as well as an oncology collaboration with fellow USA-based Trovagene. 23 May 2019
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024